Inhibikase Therapeutics (IKT) announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. Most recently Pigot served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for the Company’s therapeutic candidate in PAH.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT: